Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by whcon Jun 09, 2020 8:33pm

231 Views

Post# 31131305

RE:RE:RE:RE:People's Poll - Adjusting for Risk - Market Price June 10

I'll be happy if the price can stay at .4 or higher tomorrow. I'm pretty sure the price dropped below financing price the last two financings.

I also don't buy the argument that they need the money to talk to big pharma from a position of strength. That is why you talk to multiple companies. Any good negotiator would play the companies off against each other. If this drug is as good as they say it is, why wouldn't every company want it? Didn't Dan say a while back that their data room was really busy, that a lot of companies were interested in the drug? What's changed?

Bullboard Posts

Debt-free cannabis company set for next stage of growth